PCN5 BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES- A UK NHS PERSPECTIVE
May 1, 2005, 00:00
10.1016/S1098-3015(10)62911-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)62911-7/fulltext
Title :
PCN5 BUDGET IMPACT ANALYSIS OF INTRAVENOUS (IV) ZOLEDRONIC ACID VS. ORAL IBANDRONATE OR IV GENERIC PAMIDRONATE IN THE PREVENTION OF BONE COMPLICATIONS IN BREAST CANCER PATIENTS WITH BONE METASTASES- A UK NHS PERSPECTIVE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)62911-7&doi=10.1016/S1098-3015(10)62911-7
First page :
Section Title :
Open access? :
No
Section Order :
350